Plain-English translation of NCT07472153 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether combining immune checkpoint inhibitor medications (PD-1 or PD-L1 inhibitors) with chemotherapy—with or without an additional drug called bevacizumab—can help treat cervical cancer that has spread to other parts of the body, has come back after treatment, or could not be cured with initial surgery or radiation. The study compares these newer approaches to standard chemotherapy to see which works best for patients like you.
Cervical cancer that spreads, returns, or cannot be cured by surgery or radiation is very difficult to treat. This medication helps your immune system fight cancer cells more effectively, and researchers believe combining it with chemotherapy may offer better results than chemotherapy alone.
You likely qualify if…
You likely don't qualify if…
You would be randomly assigned to receive one of three treatment approaches: immune checkpoint inhibitors combined with chemotherapy, immune checkpoint inhibitors combined with chemotherapy plus bevacizumab, or standard chemotherapy. You would receive these medications through infusions and/or pills, likely over several months, with regular clinic visits to monitor how well the treatment is working and manage any side effects.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
Belarus